Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Advances In™ Therapies for Patients with Multiple Myeloma: More Options…More Decisions…Better Outcomes


Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

This activity, Advances In™ Therapies for Patients with Multiple Myeloma: More Options… More Decisions… Better Outcomes, is designed to update clinicians on the latest strategies to optimize outcomes for patients with multiple myeloma (MM). As clinicians who treat patients with MM, you require a solid understanding of treatment options available for patients with newly diagnosed MM, and how to tailor therapy for individual patients based on transplant eligibility and other patient and disease characteristics. It is vital to understand the benefits and risks of maintenance therapy, both in patients who undergo transplantation and in those who do not. In addition, you need to be aware of the expanding armamentarium of agents for patients with relapsed and/or refractory (R/R) MM, and the specific settings in which their use is supported by high-level clinical evidence. Finally, you want to be up-to-date on emerging agents and clinical trial options to expand opportunities for your patients with MM.

To help you meet these goals, we have developed an educational activity that features a review of the latest data and expert guidelines regarding treatment options for newly diagnosed and R/R MM, accompanied by video commentary from a leading expert in the management of patients with MM, who will discuss current treatment paradigms and strategies for integrating the latest data in order to optimize outcomes for your patients with MM.

Benefits of Participating

  • Learn how to individualize and optimize treatments for patients with newly diagnosed and relapsed/refractory multiple myeloma (MM)
  • Understand how treatment paradigms for MM are evolving with the introduction of new targeted agents
  • Learn how evolving methodologies to measure minimal residual disease may impact the management of MM in the future
  • Explore options for clinical trials investigating novel agents and new strategies for MM

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, hematologists, advanced practitioners, and nurses who treat patients with MM. Pharmacists and other healthcare professionals interested in the treatment of MM are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Individualize therapeutic selection in patients with newly diagnosed and relapsed/refractory multiple myeloma (MM)
  • Implement appropriate treatment sequencing strategies in patients with MM who experience multiple relapses or refractory disease
  • Explain the significance of minimal residual disease in patients with relapsed MM
  • Discuss the emerging MM treatment landscape and available clinical trial opportunities for eligible patients

Faculty, Staff, and Planners' Disclosures

Faculty

Alexander M. Lesokhin, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosures: Consultant, Advisory Board, or Speaker Compensation: Bristol-Myers Squibb, OncoMed Pharmaceuticals, Creative Educational Concepts, Inc., Juno Therapeutics, Dava Oncology, Syndax, GenMab, Takeda Pharmaceuticals; Research Funding: Janssen (Johnson and Johnson), Bristol-Myers Squibb, Genentech, Celgene; Royalties: Serametrix, Inc.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By